There is increasing demand for the development of manufacturing processes for bispecific antibodies in various molecular formats, which have more intricate product quality attributes. It's critical that the development of manufacturing processes is carried out with a design that allows resource efficiency, faster timeline to Tox/First-in-human (FIH) batch, and built-in flexibility.
Lonza has applied its 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This webinar highlights key approaches and technologies that enable this timeline. Case study examples are shared for application in vector, process, analytic and formulation development of bispecific molecules during pre-clinical development.